Zogenix (ZGNX) Reports Q3 Loss of $6.75

Zogenix (NASDAQ: ZGNX) reported Q3 EPS of ($6.75), versus ($1.08) reported last year.

“We were pleased to resubmit the New Drug Application (NDA) for FINTEPLA® for the treatment of seizures associated with Dravet syndrome to the U.S. Food and Drug Administration (FDA) in late September, and we expect to hear from the FDA regarding the filing status of our NDA submission shortly,” said Stephen J. Farr, Ph.D., President and CEO of Zogenix. “Following completion of enrollment in our program for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in July, we remain on track to announce top-line safety and efficacy results in the first quarter of 2020.”

“In addition, we were very excited to announce the acquisition of Modis Therapeutics and add a novel, late-stage clinical candidate, MT1621, for the treatment of patients with Thymidine Kinase 2 deficiency (TK2d), to our rare disease pipeline,” continued Dr. Farr. “Last month, safety and positive efficacy data from a global, retrospective Phase 2 study supporting the potential of MT1621 to significantly alter the course of TK2d, an often-fatal mitochondrial DNA depletion disorder, were presented.”

For earnings history and earnings-related data on Zogenix (ZGNX) click here.

You May Also Be Interested In

• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Z Squared outlines AI power strategy and Paradox Data acquisition